SIHUAN PHARM (00460) announced that its non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd. (Huisheng Bio), has received tacit approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the Investigational New Drug (IND) application of its self-developed innovative dual-target agonist P052 injection targeting glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), intended for the treatment of type 2 diabetes, overweight, or obesity.

P052 injection not only promotes insulin secretion, lowers blood glucose, and reduces body weight by activating GLP-1 receptors, but also increases energy expenditure and enhances weight loss efficacy by activating GCGR, while improving liver fat metabolism. Preclinical data show that the glucose-lowering effect of the GLP-1R/GCGR dual-target innovative drug P052 injection is similar to that of the GLP-1 single-target drug semaglutide injection, while its weight loss effect is significantly superior to semaglutide injection.

The diabetes field represents a key strategic focus for Huisheng Bio. The IND approval of the GLP-1R/GCGR dual-target agonist innovative drug P052 injection not only demonstrates Huisheng Bio's strong innovative research and development capabilities, but also marks an important step forward in diabetes drug development, injecting momentum into the group's long-term diabetes business development and further enhancing its core competitiveness and market value in the diabetes industry.